Full-Time

Agentic AI Business Solutions Director

Updated on 9/16/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

Compensation Overview

$213.1k - $288.3k/yr

Thousand Oaks, CA, USA

Hybrid

Two to three days on-site per week in Thousand Oaks, California.

Bachelor's, Master's, PhD

Category
Business & Strategy (1)
Required Skills
LLM
Data Analysis

Get referred to Amgen

See people who can refer or advise you

Requirements
  • Doctorate degree and 4 years of commercial analytics, sales planning and insights, and/or operationalizing Generative AI solutions experience; or a master's degree and 8 years of such experience; or a bachelor's degree and 10 years of such experience.
  • At least 4 years of experience directly managing people and/or leading teams, projects, programs, or directing the allocation of resources.
  • Experience in biotechnology or pharmaceutical field effectiveness, commercial analytics, field operations, commercial operations, or related functions.
  • Experience partnering with Field Leadership, Sales, Marketing, Commercial Operations, and analytics teams to solve business challenges through data, technology, analytics, and artificial intelligence.
  • Experience leading complex field technology, artificial intelligence, analytics, or commercial transformation initiatives from strategy through adoption.
  • Strong understanding of pharmaceutical field workflows, commercial data, reporting, analytics, and artificial-intelligence-enabled decision support.
  • Ability to translate complex business, data, and technology considerations into clear strategies and actionable plans.
  • Proven ability to lead cross-functional initiatives and influence senior stakeholders in a matrixed organization.
  • Ability to translate complex technical concepts into clear business implications for field, technical, and executive audiences.
  • Demonstrated success driving adoption of new technologies, capabilities, and ways of working.
  • Strong ability to manage priorities, risks, timelines, dependencies, and operational readiness.
Responsibilities
  • Define and lead the roadmap for high-impact field initiatives, prioritizing opportunities based on business value, field needs, feasibility, and enterprise priorities.
  • Partner with Field Leadership to identify opportunities to simplify workflows and embed artificial-intelligence-enabled insights, automation, and digital capabilities into the field experience.
  • Lead field-focused artificial intelligence initiatives from use-case definition and prioritization through development, deployment, adoption, and optimization.
  • Partner with BAI, Digital, Data, and Technology teams to integrate capabilities with commercial data, reporting, enterprise platforms, and field workflows.
  • Define success measures and use performance data and field feedback to continuously improve solutions and business impact.
  • Orchestrate collaboration across Field Leadership, Commercial, BAI, Digital, Data, and Technology to drive coordinated execution of field initiatives.
  • Serve as the bridge between field stakeholders and technical teams by translating business needs into actionable requirements and technical capabilities into clear business value.
  • Serve as a trusted advisor to Field Leadership and Commercial stakeholders on Agentic AI, Generative AI, analytics, automation, and digital initiatives.
  • Communicate strategy, progress, risks, adoption readiness, and business impact while ensuring field priorities and user needs inform solution decisions.
  • Drive adoption of artificial-intelligence-enabled capabilities by embedding solutions into field workflows and partnering with training, communications, and business teams on targeted enablement.
  • Define and track key performance indicators for adoption, productivity, user experience, and business impact to demonstrate value and identify improvement opportunities.
  • Lead field change management and readiness for new artificial intelligence, analytics, automation, and digital capabilities, including stakeholder engagement, communications, training, and deployment support.
  • Establish feedback loops to identify adoption barriers, prioritize enhancements, and foster continuous learning and responsible artificial intelligence adoption across the field organization.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Amgen raised 2026 revenue guidance to $38.2 billion-$39.4 billion after Q2 outperformance.
  • Repatha sales jumped 37% to $953 million, driven by cardiologist and primary-care adoption.
  • MariTide now has nine ongoing and three planned Phase 3 studies across obesity.

What critics are saying

  • Prolia and XGEVA sales fell 33% in Q2 2026 as biosimilars hit.
  • FDA proposed withdrawing TAVNEOS in April 2026, threatening a marketed rare-disease franchise.
  • If MariTide misses 2027 endpoints, Amgen loses its next obesity growth pillar.

What makes Amgen unique

  • Amgen's six growth drivers produced nearly 70% of Q2 2026 product sales.
  • IMDELLTRA sales rose 115% in Q2 2026, validating Amgen's oncology engine.
  • Hyderabad's 2027 Science and Innovation Center expands Amgen's seven-lab global R&D network.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 11th, 2026
Revolution Medicines' first pancreatic cancer therapy approval challenges Amgen's biotech dominance

Revolution Medicines received FDA approval for daraxonrasib, the first targeted therapy for metastatic pancreatic cancer, after clinical data showed it reduced death risk by more than half. The company is clinical-stage with no current revenue and posted a $1.1 billion net loss in FY 2025. Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. Free cash flow reached $8.1 billion. The company carries a debt-to-equity ratio of 6.3x. Revolution Medicines maintains a 0.1x debt-to-equity ratio and 9.5x current ratio but recorded negative free cash flow of $913.7 million. The company's pipeline targets RAS-driven tumours including lung cancer. A partnership with Royalty Pharma provides funding for development. Both companies face distinct risks: Amgen confronts pricing pressures and biosimilar competition, whilst Revolution Medicines carries clinical trial failure risks and competes against larger pharmaceutical firms.

Yahoo Finance
Sep 11th, 2026
Amgen vs CRISPR Therapeutics: Which healthcare stock offers better value in 2026?

Amgen reported revenue of $36.7 billion in FY 2025, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech giant maintains a debt-to-equity ratio of 6.3x and generated $8.1 billion in free cash flow. CRISPR Therapeutics, meanwhile, saw revenue fall 90% to $3.5 million in FY 2025, posting a net loss of $581.6 million. The gene-editing firm burns $345.9 million in cash but holds a strong current ratio of 13.3x. Its CASGEVY therapy for sickle cell disease has gained approval in the US, UK, and EU, with Vertex handling commercialisation under a 60-40 revenue split. Amgen faces pricing pressure from the Inflation Reduction Act and biosimilar competition. CRISPR Therapeutics carries clinical execution risk and ongoing intellectual property disputes.

Yahoo Finance
Sep 11th, 2026
Amgen and AstraZeneca lung cancer drug combo meets survival goal in phase III study

Amgen and AstraZeneca announced positive results from the phase III DeLLphi-305 study evaluating Amgen's Imdelltra (tarlatamab) combined with AstraZeneca's Imfinzi (durvalumab) as first-line maintenance treatment for extensive-stage small-cell lung cancer (ES-SCLC). The study met its primary endpoint of overall survival and key secondary endpoint of progression-free survival, with no new safety concerns identified. ES-SCLC affects approximately 195,000 people globally. If approved, the combination would compete with Jazz Pharmaceuticals' Zepzelca plus Roche's Tecentriq, which received FDA approval in October 2025. Imdelltra, approved in 2024 for ES-SCLC progression after platinum-based chemotherapy, generated $546 million in global sales during the first half of 2026, up from $215 million in the prior-year period.

Yahoo Finance
Sep 10th, 2026
Amgen vs. Moderna: Which healthcare stock is a better buy in 2026?

Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech serves 17 million patients globally with treatments for heart disease, obesity, and cancer. However, three distributors—McKesson, Cencora, and Cardinal Health—accounted for 77% of gross revenues, creating concentration risk. The company's debt-to-equity ratio stood at 6.3x. Moderna posted FY 2025 revenue of $1.9 billion, down 39.2% as pandemic-related vaccine demand declined. The mRNA specialist reported a net loss of $2.8 billion, resulting in a negative 145.2% net margin due to high research and development costs. The company is pivoting its mRNA platform toward infectious diseases, cancer, and rare conditions whilst expanding through partnerships like its collaboration with Merck.

Yahoo Finance
Sep 10th, 2026
Amgen trades at 17x 2026 earnings, but forecast margin expansion assumes MariTide success

Amgen trades at $393 per share, representing a trailing multiple of 23.3 times adjusted earnings. The biotech faces declining sales from Prolia and XGEVA, down 33% year-over-year to $1.1 billion in Q2 2026, due to biosimilar competition. Six key growth medicines grew 26% year-over-year, accounting for nearly 70% of Q2 product sales. Analysts forecast the forward multiple at 17.0 times for fiscal 2026 and 16.1 times for 2027. However, consensus assumes expanding profit margins whilst Amgen increases spending. Non-GAAP research spending is set to grow in high single digits for 2026, funding nine Phase III trials for MariTide, its obesity treatment candidate. Management warned of meaningful operating expense increases in Q3 2026. The valuation depends on margin expansion materialising during this investment phase.